ABC | Volume 112, Nº5, May 2019

Original Article Warpechowski Neto et al Hospital readmission – implantable devices Arq Bras Cardiol. 2019; 112(5):491-498 1. MossAJ,ZarebaW,HallWJ,KleinH,WilberDJ,CannomDS,etal;Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. 2. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49. 3. Sosa EA, de Paola AA, Martinelli M, Costa R, Pimenta J, Lorga AM, et al. [Recommendations of the Department of Arrhythmia and Clinical Electrophysiology (DAEC) of the Brazilian Cardiology Society on indications for permanent pacemaker implantation, choice of stimulation mode, and indications for automatic cardioverter-defibrillator implantation]. Arq Bras Cardiol. 1995;64(6):579-83. 4. UdoEO,ZuithoffNP,vanHemelNM,deCockCC,HendriksT,DoevendansPA,et al.Incidenceandpredictorsofshort-andlong-termcomplicationsinpacemaker therapy:theFOLLOWPACEstudy.HeartRhythm. 2012;9(5):728-35. 5. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace. 2010;12(1):103-8. 6. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-relatedcomplicationsof implantablecardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J AmColl Cardiol. 2011;58(10):995-1000. 7. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al; Heart Rhythm Society; European Heart Rhythm Association; American College of Cardiology; American Heart Association; European Society of Cardiology;HeartFailureAssociationofESC;HeartFailureSocietyofAmerica. HRS/EHRAexpertconsensusonthemonitoringofcardiovascular implantable electronicdevices (CIEDs):descriptionoftechniques, indications,personnel, frequency and ethical considerations. Heart Rhythm. 2008;5(6):907-25. 8. Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P JS, et al; Investigators of theOntario ICDDatabase. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55(8):774-82. 9. Ghani A, Delnoy PP, Ramdat Misier AR, Smit JJ, Adiyaman A, Ottervanger JP, et al. Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation. Neth Heart. J 2014;22(6):286-91. 10. Ezzat VA, Lee V, Ahsan S, ChowAW, Segal O, Rowland E, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart. 2015;2(1):e000198. 11. Tobin K, Stewart J,Westveer D, FruminH. Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. Am J Cardiol. 2000;85(6):774-6. 12. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47(12):2493-7. 13. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al; PEOPLE Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116(12):1349-55. 14. Tajstra M, Gadula-Gacek E, Kurek A, Adamowicz-Czoch E, Olszowski D, Ostr ę gaM, et al. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights fromSilesianCenter Defibrillator registry. Cardiol J. 2017;24(5):515-22. 15. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, Cerisier A, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta- analysis. Circulation. 1998;97(18):1796-801. References period of less than 1 year. In contrast, the implant-related unscheduled hospital visit rate does not differ between the groups. Acknowledgment The authors thank the Research Unit of the Cardiology Institute / University Foundation of Cardiology for the technical support in the publication of this work. Author contributions Conception and design of the research, analysis and interpretation of the data and writing of the manuscript: Warpechowski Neto S, Ley LLG, Almeida ED, SaffMAL, Dutra LZ, LeyALG, Sant`AnnaRT, LimaGG, Kalil RAK, Leiria TLL; acquisition of data: Warpechowski Neto S, Ley LLG, Almeida ED, Saff MAL, Dutra LZ, Ley ALG, Lima GG, Kalil RAK; statistical analysis: Warpechowski Neto S, Ley LLG, Almeida ED, Dutra LZ, Ley ALG, Sant`Anna RT, Lima GG, Leiria TLL; obtaining funding: Kalil RAK, LeiriaTLL; critical revisionof themanuscript for intellectual content: Warpechowski Neto S, Ley LLG, Almeida ED, SaffMAL, Dutra LZ, Ley ALG, Sant`Anna RT, Lima GG, Kalil RAK, Leiria TLL. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was funded by FAPPIC (Fundo de Apoio à Pesquisa do Instituto de Cardiologia / Fundação Universitária de Cardiologia). Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Instituto de Cardiologia/Fundação Universitária de Cardiologia under the protocol number 5374/17. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 497